Kairos Pharma has signed a binding agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics, a company backed by OrbiMed and Torrey Pines Investment.
CL-273 is a reversible, investigational, wild-type-sparing pan epidermal growth factor receptor (EGFR) small molecule inhibitor developed using an AI-based drug discovery platform.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The asset specifically targets resistant mutations that arise during treatment with EGFR tyrosine kinase inhibitors, addressing drug resistance in non-small cell lung cancer (NSCLC) with EGFR mutations.
The acquisition aims to expedite the development of next-generation targeted therapies for EGFR mutant NSCLC patients globally.
Kairos Pharma CEO John Yu said: “The signing of binding terms to acquire CL‑273 represents a pivotal step in building Kairos Pharma’s next generation of targeted therapies for EGFR mutant lung cancer.
“This transaction is expected to be value accretive. CL‑273’s AI-designed, wild-type sparing pan EGFR profile positions it as a potentially best-in-class asset in a large, fast-growing $16.2bn lung cancer market with significant unmet needs due to the development of resistance. Given its prestigious backing, we believe partnering with Celyn Therapeutics offers additional high-quality science to our existing pipeline.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We believe in the rigour of the data package supporting CL‑273. We further believe that together with an OrbiMed-backed innovator, Kairos Pharma is strongly positioned to deliver a highly differentiated, potentially best-in-class, EGFR inhibitor to patients worldwide.”
Celyn Therapeutics contributes its experience in small-molecule oncology drug development.
D. Boral Capital served as the exclusive financial adviser for this deal.
Kairos Pharma’s lead candidate, ENV-105, is undergoing a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for NSCLC.
ENV-105 has not yet received approval from the US Food and Drug Administration (FDA) or any other regulator.
